<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JPP</journal-id>
<journal-id journal-id-type="hwp">spjpp</journal-id>
<journal-title>Journal of Pharmacy Practice</journal-title>
<issn pub-type="ppub">0897-1900</issn>
<issn pub-type="epub">1531-1937</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0897190012448310</article-id>
<article-id pub-id-type="publisher-id">10.1177_0897190012448310</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacogenomics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical Pharmacogenomics of Warfarin and Clopidogrel</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Shin</surname>
<given-names>Jaekyu</given-names>
</name>
<degrees>PharmD, MS, BCPS</degrees>
<xref ref-type="aff" rid="aff1-0897190012448310">1</xref>
<xref ref-type="corresp" rid="corresp1-0897190012448310"/>
</contrib>
<aff id="aff1-0897190012448310"><label>1</label>Department of Clinical Pharmacy, University of California, San Francisco, CA, USA</aff>
</contrib-group>
<contrib-group content-type="issue">
<contrib contrib-type="guest-editor">
<name>
<surname>Saltiel</surname>
<given-names>Manny</given-names>
</name>
<degrees>PharmD, FASHP, FCCP</degrees>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0897190012448310">Jaekyu Shin, 521 Parnassus Avenue, Room C152, Box 0622, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco CA 94143, USA Email: <email>shinj@pharmacy.ucsf.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>25</volume>
<issue>4</issue>
<fpage>428</fpage>
<lpage>438</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Genetic polymorphisms significantly influence responses to warfarin and clopidogrel. Polymorphisms in the cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase genes change warfarin pharmacokinetics and pharmacodynamics, respectively. Because these polymorphisms influence warfarin dose requirements, they may primarily help determine therapeutic warfarin doses in patients who newly start on the drug. To assist in estimating therapeutic warfarin doses, the warfarin label provides a pharmacogenomic dosing table and various warfarin pharmacogenomic dosing algorithms are available. On the other hand, polymorphisms in the <italic>CYP2C19</italic> gene affect clopidogrel pharmacokinetics. These polymorphisms may be useful to identify clopidogrel nonresponders who may benefit from taking an alternative antiplatelet agent such as prasugrel and ticagrelor. Although both drugs have pharmacogenomic tests available for clinical use, their clinical utilities have not been established and are currently being actively studied. In this review, clinical application of warfarin and clopidogrel pharmacogenomics will be focused. With the current level of evidence, potential patients who may get benefit from warfarin and clopidogrel pharmacogenomic testing will be discussed. In addition, the interpretation of the warfarin and clopidogrel test results and the current barriers to widespread use of warfarin and clopidogrel pharmacogenomic testing will be discussed.</p>
</abstract>
<kwd-group>
<kwd>warfarin</kwd>
<kwd>clopidogrel</kwd>
<kwd>pharmacogenomics</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0897190012448310">
<title>Introduction</title>
<p>Warfarin and clopidogrel are 2 cardiovascular drugs that share many features. Therapeutically, both drugs influence hemostasis. Warfarin, an anticoagulant, inhibits the production of vitamin K-dependent coagulation factors; whereas clopidogrel, an antiplatelet, antagonizes P2Y12 receptors in the platelet aggregation pathway. These 2 widely used drugs have high interindividual variability in their responses. Importantly, genetic polymorphisms have been shown to be a major contributor to the interindividual response variability. Cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase subunit 1 (<italic>VKORC1</italic>) are genes of which polymorphisms influence warfarin response. On the other hand, the <italic>CYP2C19</italic> polymorphisms are a major determinant of clopidogrel response. Because of these genetic influences, both drugs have pharmacogenomic information on their labels. In addition, both drugs have pharmacogenomic tests available for clinical use. Some of these tests have been cleared by the Food and Drug Administration (FDA) as in vitro diagnostic devices. Thus, these 2 drugs may be good examples of how pharmacogenomics can be used in clinical practice.</p>
<p>In this article, the genetic influences on warfarin and clopidogrel responses will be reviewed and their clinical application will be discussed.</p>
<sec id="section2-0897190012448310">
<title>Warfarin</title>
<p>Warfarin dose requirements are highly variable among patients.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012448310">1</xref>
</sup> Studies have reported up to a 20-fold difference in warfarin dose requirements.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012448310">1</xref>
</sup> This high interindividual variability in warfarin dose requirements may contribute to the high incidence of adverse events by warfarin such as bleeding. Both genetic and nongenetic factors cause interindividual warfarin dose variability.<sup>
<xref ref-type="bibr" rid="bibr2-0897190012448310">2</xref>
</sup> Of the genetic factors, polymorphisms in the <italic>CYP2C9</italic> and <italic>VKORC1</italic> genes have been consistently associated with warfarin dose variability.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012448310">1</xref>
<xref ref-type="bibr" rid="bibr2-0897190012448310"/>
<xref ref-type="bibr" rid="bibr3-0897190012448310"/>–<xref ref-type="bibr" rid="bibr4-0897190012448310">4</xref>
</sup> The <italic>CYP2C9</italic> polymorphisms affect warfarin pharmacokinetics and the <italic>VKORC1</italic> polymorphisms change warfarin pharmacodynamics. Three loci in the <italic>CYP2C9</italic> and <italic>VKORC1</italic> genes are included on the warfarin label: <italic>CYP2C9</italic>*2, <italic>CYP2C9</italic>*3, and <italic>VKORC1</italic>-1639G/A (or its equivalent).<sup>
<xref ref-type="bibr" rid="bibr5-0897190012448310">5</xref>
</sup> The following sections will focus on the effect of these 3 alleles on warfarin dose requirements.</p>
</sec>
<sec id="section3-0897190012448310">
<title>
<italic>CYP2C9</italic> Polymorphisms</title>
<p>Warfarin is a racemic drug and S-warfarin has 3 to 5 more potent anticoagulation effects than R-warfarin.<sup>
<xref ref-type="bibr" rid="bibr6-0897190012448310">6</xref>
</sup> The <italic>CYP2C9</italic> gene encodes an enzyme responsible for metabolizing S-warfarin.<sup>
<xref ref-type="bibr" rid="bibr6-0897190012448310">6</xref>
</sup> This gene contains more than 35 alleles and, of these alleles, the *2 and *3 alleles have been well studied.<sup>
<xref ref-type="bibr" rid="bibr7-0897190012448310">7</xref>
</sup> The <italic>CYP2C9</italic>*2 allele changes an amino acid (Arg144Cys) on the outer surface of the enzyme, whereas the <italic>CYP2C9</italic>*3 allele substitutes an amino acid (Ile359Leu) on the interior of the enzyme.<sup>
<xref ref-type="bibr" rid="bibr8-0897190012448310">8</xref>
</sup> Both of the alleles decrease the coupling efficiency of a substrate and nicotinamide adenine dinucleotide phosphate, a cofactor of the catalytic reaction.<sup>
<xref ref-type="bibr" rid="bibr8-0897190012448310">8</xref>
</sup> As a result, carriers of these alleles have lower warfarin-metabolizing activity and warfarin dose requirements. The *1/*2 and *1/*3 genotypes require 20% and 35% lower warfarin doses than the *1/*1 genotype.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012448310">1</xref>,<xref ref-type="bibr" rid="bibr9-0897190012448310">9</xref>
</sup> The *1/*3 genotype requires a lower warfarin dose than the *1/*2 genotype because the *3 allele reduces warfarin-metabolizing activity to a greater degree than the *2 allele.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012448310">1</xref>
</sup> Of note, the *3/*3 genotype requires about an 80% lower warfarin dose than the *1/*1 genotype.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012448310">1</xref>
</sup>
</p>
<p>The prevalence of these <italic>CYP2C9</italic> alleles differs by race (<xref ref-type="table" rid="table1-0897190012448310">Table 1</xref>). The *2 and *3 alleles are more common in caucasians than in the other races. Of note, the *2 allele is rare in Asians.</p>
<table-wrap id="table1-0897190012448310" position="float">
<label>Table 1.</label>
<caption>
<p>Prevalence of the Common <italic>CYP2C9</italic> Variant Alleles by Race (%)</p>
</caption>
<graphic alternate-form-of="table1-0897190012448310" xlink:href="10.1177_0897190012448310-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Caucasians</th>
<th>African Americans</th>
<th>Asians</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2C9*2</td>
<td>20-24</td>
<td>3-4</td>
<td>&lt;1</td>
</tr>
<tr>
<td>CYP2C9*3</td>
<td>11-12</td>
<td>1-3</td>
<td>8-9</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0897190012448310">
<p>Abbreviation: <italic>CYP2C9</italic>, cytochrome P450 2C9.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The <italic>CYP2C9</italic> polymorphisms may have many implications of warfarin management. First, the <italic>CYP2C9</italic> variant alleles have been associated with an increased risk of a supratherapeutic international normalized ratio (INR).<sup>
<xref ref-type="bibr" rid="bibr10-0897190012448310">10</xref>
<xref ref-type="bibr" rid="bibr11-0897190012448310"/>–<xref ref-type="bibr" rid="bibr12-0897190012448310">12</xref>
</sup> In addition, they increase the risk of bleeding in patients on warfarin by about 2-fold.<sup>
<xref ref-type="bibr" rid="bibr13-0897190012448310">13</xref>
</sup> Therefore, carriers of a variant allele should be more closely monitored for INR and bleeding when they are on warfarin. Finally, the <italic>CYP2C9</italic> variant alleles may increase the time to reach a therapeutic INR because they may prolong a half-life of warfarin by reducing its clearance.<sup>
<xref ref-type="bibr" rid="bibr14-0897190012448310">14</xref>
</sup>
</p>
</sec>
<sec id="section4-0897190012448310">
<title>
<italic>VKORC1</italic> Polymorphisms</title>
<p>The <italic>VKORC1</italic> gene encodes vitamin K epoxide reductase, a key enzyme involved in the vitamin K recycling process and warfarin target protein.<sup>
<xref ref-type="bibr" rid="bibr6-0897190012448310">6</xref>
</sup> The <italic>VKORC1</italic>-1639G/A polymorphism is located in the promoter region and influences the transcription of the gene: the G allele is associated with a larger amount of the vitamin K epoxide reductase messenger RNA (mRNA) than the A allele.<sup>
<xref ref-type="bibr" rid="bibr15-0897190012448310">15</xref>
</sup> As a result, the <italic>VKORC1</italic>-1639 G allele requires a higher warfarin dose than the <italic>VKORC1</italic>-1639A allele. Studies have shown that the GG, GA, and AA genotypes require 6 mg/d, 5 mg/d, and 3 mg/d of warfarin, respectively.<sup>
<xref ref-type="bibr" rid="bibr3-0897190012448310">3</xref>,<xref ref-type="bibr" rid="bibr16-0897190012448310">16</xref>
</sup>
</p>
<p>The prevalence of the <italic>VKORC1</italic> polymorphism differs by race (<xref ref-type="table" rid="table2-0897190012448310">Table 2</xref>). Of note, over 85% of Asians carry the <italic>VKORC1</italic>-1639A allele, whereas about 40% of caucasians and 20% of African Americans carry the allele.<sup>
<xref ref-type="bibr" rid="bibr3-0897190012448310">3</xref>
</sup> This racial difference in the frequency of the <italic>VKORC1</italic>-1639 A allele may explain, in part, why Asians require a lower warfarin dose than the other races.</p>
<table-wrap id="table2-0897190012448310" position="float">
<label>Table 2.</label>
<caption>
<p>Prevalence of the <italic>VKORC1-1639G/A</italic> Polymorphism by Race (%)</p>
</caption>
<graphic alternate-form-of="table2-0897190012448310" xlink:href="10.1177_0897190012448310-table2.tif"/>
<table>
<thead>
<tr>
<th>Allele</th>
<th>Caucasians</th>
<th>African Americans</th>
<th>Asians</th>
</tr>
</thead>
<tbody>
<tr>
<td>-1639 G (or 1137 C)</td>
<td>57-58</td>
<td>49-58</td>
<td>10-14</td>
</tr>
<tr>
<td>-1639 A (or 1137 T)</td>
<td>37-42</td>
<td>14-21</td>
<td>85-89</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0897190012448310">
<p>Abbreviations: <italic>VKORC1</italic>, vitamin K epoxide reductase complex subunit 1; G, guanine; A, adenine; C, cytosine; T, thymine.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The <italic>VKORC1</italic> polymorphism may have many clinical implications. The polymorphisms has been associated with an increased risk of a supratherapeutic INR.<sup>
<xref ref-type="bibr" rid="bibr10-0897190012448310">10</xref>,<xref ref-type="bibr" rid="bibr13-0897190012448310">13</xref>
</sup> However, it does not appear to be associated with an increased risk of bleeding.<sup>
<xref ref-type="bibr" rid="bibr17-0897190012448310">17</xref>
</sup> The <italic>VKORC1</italic>-1639AA genotype may have a reduced time to reach the first therapeutic INR and the first INR above 4.<sup>
<xref ref-type="bibr" rid="bibr18-0897190012448310">18</xref>
</sup>
</p>
<p>The <italic>CYP2C9</italic> and <italic>VKORC1</italic> polymorphisms influence warfarin doses independent of each other.<sup>
<xref ref-type="bibr" rid="bibr3-0897190012448310">3</xref>
</sup> Of the <italic>CYP2C9</italic> and <italic>VKORC1</italic> genotype combinations, the <italic>CYP2C9</italic>*1/*1 and <italic>VKORC1</italic>-1639G/G genotype combination requires the highest warfarin dose, typically 6 to 7 mg/d.<sup>
<xref ref-type="bibr" rid="bibr19-0897190012448310">19</xref>
</sup> On the other hand, the <italic>CYP2C9</italic>*3/*3 and <italic>VKORC1</italic>-1639A/A genotype combination requires the lowest warfarin dose, 1 to 2 mg/d.<sup>
<xref ref-type="bibr" rid="bibr19-0897190012448310">19</xref>
</sup> The <italic>CYP2C9</italic> and <italic>VKORC1</italic> polymorphisms contribute to 10% to 30% of the total interindividual variability in warfarin doses.<sup>
<xref ref-type="bibr" rid="bibr20-0897190012448310">20</xref>,<xref ref-type="bibr" rid="bibr21-0897190012448310">21</xref>
</sup>
</p>
</sec>
<sec id="section5-0897190012448310">
<title>Warfarin Pharmacogenomic Tests</title>
<p>As of August 1, 2011, 4 warfarin pharmacogenomic tests are available as in vitro diagnostic devices (<xref ref-type="table" rid="table3-0897190012448310">Table 3</xref>). One tests genotypes for the <italic>VKORC1</italic> 1137C/T polymorphism because this polymorphism is in complete linkage disequilibrium with the <italic>VKORC1</italic>-1639 G/A polymorphism.<sup>
<xref ref-type="bibr" rid="bibr3-0897190012448310">3</xref>
</sup> All of these tests have a short assay performance time (&lt;8 hours), an important characteristics making genotype-guided warfarin initiation feasible on the same day when testing is ordered. However, there are several obstacles to the widespread use of the tests in clinical practice. First, the FDA-cleared warfarin pharmacogenomic tests do not include polymorphisms other than <italic>CYP2C9</italic>*2, <italic>CYP2C9</italic>*3, and <italic>VKORC1</italic>-1639G/A (or 1173C/T). Although these 3 loci explain the majority of warfarin dose variability contributed by genetic polymorphisms, other genetic variants such as <italic>CYP2C9</italic>*5, *6, *8, *11, and <italic>CYP4F2</italic> Val433Met have also been associated with warfarin dose variability.<sup>
<xref ref-type="bibr" rid="bibr22-0897190012448310">22</xref>,<xref ref-type="bibr" rid="bibr23-0897190012448310">23</xref>
</sup> In particular, <italic>CYP2C9</italic>*5, *6, *8, and *11 are common in African Americans with a prevalence of 1% to 12% and have been associated with warfarin dose variability in this population.<sup>
<xref ref-type="bibr" rid="bibr22-0897190012448310">22</xref>
</sup> Thus, the current warfarin pharmacogenomic tests may have a limited role in predicting warfarin doses in African Americans. Second, the warfarin pharmacogenomic tests do not predict unusually high warfarin doses (eg, 15 mg/d). The <italic>CYP2C9</italic>*1/*1 and <italic>VKORC1</italic>-1639G/G genotype combination typically requires 6 to 7 mg/d.<sup>
<xref ref-type="bibr" rid="bibr19-0897190012448310">19</xref>
</sup> Rare <italic>VKORC1</italic> mutations in the coding region such as Asp36Tyr have been associated with the unusually high warfarin doses.<sup>
<xref ref-type="bibr" rid="bibr24-0897190012448310">24</xref>
</sup> However, these mutations are not included in the current warfarin pharmacogenomic tests. Third, the tests are not widely available. Only about 20% of the hospitals in North America have an in-house warfarin pharmacogenomic test available.<sup>
<xref ref-type="bibr" rid="bibr25-0897190012448310">25</xref>
</sup> This unavailability of a test in many hospitals may make a timely genotype-guided warfarin initiation unfeasible because of a delayed turnaround time. Fourth, the cost of warfarin pharmacogenomic testing ($300-500) is rarely reimbursed by an insurance plan. Only 2 situations may make the testing eligible for reimbursement. (1) If a patient has a high risk of bleeding, the testing may be reimbursed with a prior authorization. (2) If a patient participates in a randomized, controlled clinical trial assessing clinical outcomes of warfarin pharmacogenomic testing (eg, mortality, bleeding, thrombosis etc), the Centers for Medicare and Medicaid Services cover the testing to support the development of evidence for Medicare beneficiaries.<sup>
<xref ref-type="bibr" rid="bibr26-0897190012448310">26</xref>
</sup> Reimbursability for a new technology appears to be dependent on whether it is recommended in guidelines of a professional organization.<sup>
<xref ref-type="bibr" rid="bibr27-0897190012448310">27</xref>
</sup> No guidelines currently recommend warfarin pharmacogenomic testing because of the inconclusive clinical utility data. Finally, cost-effectiveness of warfarin pharmacogenomic testing has not been established. Studies have suggested that the testing has a 10% to 48% chance of quality-adjusted life year (QALY) less than $50 000, an important criterion for the determination of cost-effectiveness.<sup>
<xref ref-type="bibr" rid="bibr28-0897190012448310">28</xref>
<xref ref-type="bibr" rid="bibr29-0897190012448310"/>–<xref ref-type="bibr" rid="bibr30-0897190012448310">30</xref>
</sup> However, the cost-effectiveness of warfarin pharmacogenomic testing largely depends on the clinical utility of the testing which is currently unknown. In addition, testing cost and turnaround time also influence the cost-effectiveness of testing because testing was cost effective if it is &lt;$200, has a turnaround time of less than 24 hours, and prevents greater than 32% of major bleeding.<sup>
<xref ref-type="bibr" rid="bibr28-0897190012448310">28</xref>
</sup> Since whole genome scanning costs have been significantly reduced, this rapid advance in genotyping technology is likely to reduce the cost and turnaround time. Given the importance of clinical utility data, the ongoing clinical trials evaluating clinical utility of the testing will help determine the cost-effectiveness of warfarin pharmacogenomic testing.</p>
<table-wrap id="table3-0897190012448310" position="float">
<label>Table 3.</label>
<caption>
<p>Warfarin Pharmacogenomic Tests Cleared by the Food and Drug Administration</p>
</caption>
<graphic alternate-form-of="table3-0897190012448310" xlink:href="10.1177_0897190012448310-table3.tif"/>
<table>
<thead>
<tr>
<th>Assay Name</th>
<th>
<italic>CYP2C9</italic> Alleles Tested</th>
<th>
<italic>VKORC1</italic> Allele Tested</th>
<th>Assay Performance Time (hour)</th>
</tr>
</thead>
<tbody>
<tr>
<td>eQ-PRC LC Warfarin Genotyping KIT</td>
<td>*2 and *3</td>
<td>-1639G/A</td>
<td>≤ 2</td>
</tr>
<tr>
<td>eSensor<sup>®</sup> Warfarin Sensitivity</td>
<td>*2 and *3</td>
<td>-1639G/A</td>
<td>3-4</td>
</tr>
<tr>
<td>Infiniti 2C9-<italic>VKORC1</italic> Multiplex Assay for warfarin</td>
<td>*2 and *3</td>
<td>-1639G/A</td>
<td>6-8</td>
</tr>
<tr>
<td>The Verigene<sup>®</sup> Warfarin Metabolism Nucleic Acid Test</td>
<td>*2 and *3</td>
<td>1137C/T</td>
<td>≤ 2</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0897190012448310">
<p>Abbreviations: CYP, cytochrome P450; <italic>VKORC1</italic>, vitamin K epoxide reductase complex subunit 1; G, guanine; A, adenine; C, cytosine; T, thymine.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section6-0897190012448310">
<title>Evidence to Support Using Warfarin Pharmacogenomic Testing in Clinical Practice</title>
<p>The Centers for Disease Control and Prevention (CDC) has established criteria to evaluate a genetic test for clinical use.<sup>
<xref ref-type="bibr" rid="bibr31-0897190012448310">31</xref>
</sup> These criteria include analytical validity, clinical validity, clinical utility, and ethical, legal, and social implications. Analytical validity is defined as the ability of a genetic test to accurately and reliably measure the genotype of interest. Clinical validity is the ability of a genetic test to accurately and reliably predict the disorder or phenotype of interest. Clinical utility is the evidence of improved measurable clinical outcomes, as well as its usefulness and added value to patient management decision making compared with current management without genetic testing. Ethical, legal, and social implications of a genetic test are contextual issues involving the use of a test in clinical practice.</p>
<p>Warfarin pharmacogenomic tests have good analytical and clinical validity. However, their clinical utility has not been established. A recent study reported that patients undergoing warfarin pharmacogenomic testing had fewer hospitalizations for any cause including bleeding or thromboembolism during the 6-month follow-up period compared with historical controls.<sup>
<xref ref-type="bibr" rid="bibr32-0897190012448310">32</xref>
</sup> However, these data may not be used to support clinical utility of the testing because clinical utility of a genetic test may be best proved in a randomized trial comparing clinical outcomes in patients with and without testing. Four randomized trials have assessed clinical utility of warfarin pharmacogenomic testing.<sup>
<xref ref-type="bibr" rid="bibr19-0897190012448310">19</xref>,<xref ref-type="bibr" rid="bibr33-0897190012448310">33</xref>
<xref ref-type="bibr" rid="bibr34-0897190012448310"/>–<xref ref-type="bibr" rid="bibr35-0897190012448310">35</xref>
</sup> The first trial conducted in 191 patients in Israel compared a <italic>CYP2C9</italic> genotype-based warfarin dosing with a published clinical algorithm-based dosing for the time to reach the therapeutic INR range (ie, first INR &gt;2.0).<sup>
<xref ref-type="bibr" rid="bibr33-0897190012448310">33</xref>
</sup> The genotype-based warfarin dosing significantly shortened the time to reach the therapeutic INR compared with the clinical algorithm-based dosing (14.1 ± 6.9 days in the genotype-based dosing group vs 32.2 ± 21.1 days in the clinical algorithm-based dosing group). In addition, the genotype-based warfarin dosing significantly reduced the incidence of bleeding by 9.3% (3.2% vs 12.5%). Of interest, this study used only a <italic>CYP2C9</italic> genotype-based warfarin dosing algorithm, whereas the other trials adopted a <italic>CYP2C9</italic> and <italic>VKORC1</italic> genotype combination-based warfarin dosing algorithm. The second trial conducted in 206 mostly caucasian patients compared genotype-based warfarin dosing with a published nomogram-based dosing for the percentage of out-of-range INRs in the first 90 days of warfarin therapy.<sup>
<xref ref-type="bibr" rid="bibr19-0897190012448310">19</xref>
</sup> In this study, the genotype-based warfarin dosing did not decrease the percentage of out-of-range INRs compared with the nomogram-based dosing (30.7% vs 33.1%, respectively). Of note, a dedicated anticoagulation pharmacist managed the nomogram-based warfarin dosing in this study. The third study conducted in 122 Chinese patients with heart valve replacement compared genotype-based warfarin dosing with a fixed starting dosing (2 mg/d) for the time to a stable warfarin dose.<sup>
<xref ref-type="bibr" rid="bibr34-0897190012448310">34</xref>
</sup> In this study, the genotype-based dosing significantly reduced the time to reach a stable warfarin dose (median 24 days vs 35 days, <italic>P</italic> &lt; .001). However, the genotype-based dosing did not decrease the incidence of adverse outcomes such as bleeding (11.5% vs 13.3%, <italic>P</italic> = .76). Of note, the study has the target INR between 1.8 and 3.0, which is different from the recommendations in the guidelines.<sup>
<xref ref-type="bibr" rid="bibr36-0897190012448310">36</xref>
</sup> The most recent trial enrolled 230 patients with Caucasian ancestry evaluated absolute prediction error relative to the therapeutic dose and the time in therapeutic range during the first 14 days.<sup>
<xref ref-type="bibr" rid="bibr35-0897190012448310">35</xref>
</sup> In this study, the comparator group used a clinical algorithm-based warfarin dosing. Although the genotype-based dosing group nominally had a lower absolute prediction error than the clinical algorithm-based dosing group (0.8 mg/d vs 1.32 mg/d), the study did not report a <italic>P</italic> value. In addition, the time in therapeutic range during the first 14 days was not significantly different between the groups (30.8% ± 28.4% vs 29.1% ± 15.5%, <italic>P</italic> = .56).</p>
<p>Although these 4 trials have provided preliminary data on clinical utility of warfarin pharmacogenomic testing, they suffer from flaws in design. They have a small sample size (n ≤ 230) and comprised homogenous population. In addition, they used surrogate outcomes such as time to reach the therapeutic INR and percentage of out-of-range INR because of their small sample size and short duration. Moreover, they used warfarin pharmacogenomic dosing algorithms which may not be the most accurate among warfarin pharmacogenomic dosing algorithms.<sup>
<xref ref-type="bibr" rid="bibr37-0897190012448310">37</xref>
</sup> Therefore, their data are inconclusive. Clinical utility of warfarin pharmacogenomic testing is currently being evaluated in studies addressing these problems. These studies include the Clarification of Optimal Anticoagulation through Genetics (COAG), the Genetics Informatics Trial (GIFT) of Warfarin to Prevent Deep Venous Thrombosis, the Clinical, Economic Implication of Genetic Testing for Warfarin Management trial, and the European Pharmacogenomics of Anticoagulation Trial (EU-PACT). Because of the importance of the clinical utility, the results of these studies, which are expected to be provided between March 2012 and August 2014, will likely impact on the clinical adoption of warfarin pharmacogenomic testing.<sup>
<xref ref-type="bibr" rid="bibr38-0897190012448310">38</xref>
</sup>
</p>
</sec>
<sec id="section7-0897190012448310">
<title>Clinical Application of Warfarin Pharmacogenomic Testing</title>
<sec id="section8-0897190012448310">
<title>Who may be tested?</title>
<p>
<italic>C</italic>urrently, no consensus has been made regarding who should receive warfarin pharmacogenomic testing largely due to the inconclusive clinical utility data. Some experts have suggested that warfarin pharmacogenomic testing may be offered to patients who (1) have never been on warfarin, (2) have a target INR range of 2 to 3 and (3) are at high risk of bleeding. This recommendation is based on the following: (1) if a patient has been on warfarin in the past, a therapeutic warfarin dose has likely been established; (2) the majority of warfarin pharmacogenomic studies have been conducted in patients who had a target INR range of 2 to 3; and (3) the 3 loci assessed by an FDA-cleared warfarin pharmacogenomic test have been associated with an increased risk of overanticoagulation.<sup>
<xref ref-type="bibr" rid="bibr2-0897190012448310">2</xref>,<xref ref-type="bibr" rid="bibr3-0897190012448310">3</xref>,<xref ref-type="bibr" rid="bibr17-0897190012448310">17</xref>,<xref ref-type="bibr" rid="bibr39-0897190012448310">39</xref>,<xref ref-type="bibr" rid="bibr40-0897190012448310">40</xref>
</sup> Some commercial insurance plans may cover the cost of the testing for this group of patients with a prior authorization.</p>
<p>
<italic>When should the test results be available? </italic>Ideally, warfarin pharmacogenomic test results should be available before the first dose of warfarin. However, the results can still be used if they are available before the sixth dose of warfarin and the www.warfarindosing.org algorithm is used.<sup>
<xref ref-type="bibr" rid="bibr40-0897190012448310">40</xref>
</sup> This warfarin pharmacogenomic dosing algorithm can adjust warfarin doses by taking into account previous INR values and doses of warfarin before the sixth dose. This algorithm is also accurate in predicting therapeutic warfarin doses.<sup>
<xref ref-type="bibr" rid="bibr37-0897190012448310">37</xref>
</sup>
</p>
</sec>
<sec id="section9-0897190012448310">
<title>How can the test results be applied to patient care?</title>
<p>Two tools are mainly used to estimate the stable warfarin doses: the warfarin pharmacogenomic dosing table on the warfarin labeling and warfarin pharmacogenomic dosing algorithms. The warfarin pharmacogenomic dosing table provides a range of expected therapeutic warfarin doses based on <italic>CYP2C9</italic> and <italic>VKORC1</italic> genotype combinations (<xref ref-type="table" rid="table4-0897190012448310">Table 4</xref>).<sup>
<xref ref-type="bibr" rid="bibr5-0897190012448310">5</xref>
</sup> Warfarin pharmacogenomic dosing algorithms are linear regression models with coefficients of determination ranging 40% to 60%.<sup>
<xref ref-type="bibr" rid="bibr2-0897190012448310">2</xref>,<xref ref-type="bibr" rid="bibr20-0897190012448310">20</xref>,<xref ref-type="bibr" rid="bibr40-0897190012448310">40</xref>
</sup> These genotype-based warfarin dosing tools more accurately predict therapeutic warfarin doses than the nongenotype-based warfarin dosing methods (eg, fixed dosing and clinical dosing algorithm–based methods).<sup>
<xref ref-type="bibr" rid="bibr41-0897190012448310">41</xref>
</sup> In addition, a pharmacogenomic dosing algorithm–based method appears be more accurate in predicting therapeutic warfarin doses than the pharmacogenomic dosing table–based method.<sup>
<xref ref-type="bibr" rid="bibr41-0897190012448310">41</xref>
</sup> In a study directly comparing various dosing methods, a pharmacogenomic dosing algorithm-based method had a significantly higher percentage of patients whose predicted therapeutic doses were within 20% of the actual doses (52%) than the other dosing methods (the dosing table on the warfarin labeling, 43%; a clinical dosing algorithm, 39%; a 5 mg/d fixed dosing, 37%).<sup>
<xref ref-type="bibr" rid="bibr41-0897190012448310">41</xref>
</sup> Because of the additional 10% to 30% contributions to warfarin dose variability made by the <italic>CYP2C9</italic> and <italic>VKORC1</italic> polymorphisms, genotype-based warfarin dosing methods are more accurate than the nongenotype-based ones. The pharmacogenomic table–based dosing is less accurate than the pharmacogenomic algorithm–based dosing, in part, because the table does not contain a dose range &gt;7 mg/d and may not fully account for important clinical factors affecting warfarin dose requirements such as amiodarone use.<sup>
<xref ref-type="bibr" rid="bibr42-0897190012448310">42</xref>
</sup>
</p>
<table-wrap id="table4-0897190012448310" position="float">
<label>Table 4.</label>
<caption>
<p>Range of Expected Therapeutic Warfarin Doses Based on the <italic>CYP2C9</italic> and <italic>VKORC1</italic> Genotype</p>
</caption>
<graphic alternate-form-of="table4-0897190012448310" xlink:href="10.1177_0897190012448310-table4.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">
<italic>VKORC1</italic>-1639</th>
<th colspan="6">
<italic>CYP2C9</italic>
</th>
</tr>
<tr>
<th>*1/*1</th>
<th>*1/*2</th>
<th>*1/*3</th>
<th>*2/*2</th>
<th>*2/*3</th>
<th>*3/*3</th>
</tr>
</thead>
<tbody>
<tr>
<td>GG</td>
<td>5-7</td>
<td>5-7</td>
<td>3-4</td>
<td>3-4</td>
<td>3-4</td>
<td>0.5-2</td>
</tr>
<tr>
<td>GA</td>
<td>5-7</td>
<td>3-4</td>
<td>3-4</td>
<td>3-4</td>
<td>0.5-2</td>
<td>0.5-2</td>
</tr>
<tr>
<td>AA</td>
<td>3-4</td>
<td>3-4</td>
<td>0.5-2</td>
<td>0.5-2</td>
<td>0.5-2</td>
<td>0.5-2</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0897190012448310">
<p>Abbreviations: <italic>CYP2C9</italic>, cytochrome P450 2C9; <italic>VKORC1</italic>, vitamin K epoxide reductase complex subunit 1; G, guanine; A, adenine.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>To date, more than 40 warfarin pharmacogenomic dosing algorithms have been reported. Among these algorithms, the www.warfarindosing.org and International Warfarin Pharmacogenomics Consortium algorithms appear to be most accurate.<sup>
<xref ref-type="bibr" rid="bibr37-0897190012448310">37</xref>
</sup> These 2 algorithms had 45% to 54% of patients whose predicted therapeutic warfarin doses were within 20% of the actual doses. In addition, they performed similarly across racial groups but performed better for doses &gt;3 mg/d and &lt;7 mg/d than for doses ≤3 mg/d or ≥7 mg/d.<sup>
<xref ref-type="bibr" rid="bibr37-0897190012448310">37</xref>
</sup>
</p>
<p>Although convenient to use and potentially clinically useful, the warfarin pharmacogenomic algorithms have many limitations. Warfarin pharmacogenomic dosing algorithms have a variable accuracy by a therapeutic warfarin dose range. They are most accurate for warfarin doses 3 to 7 mg/d and least accurate for doses &gt;7 mg/d.<sup>
<xref ref-type="bibr" rid="bibr37-0897190012448310">37</xref>
</sup> In particular, they do not predict unusually high doses (eg, 15 mg/d) because the <italic>CYP2C9</italic> and <italic>VKORC1</italic> genotype combinations are not associated with warfarin resistance.<sup>
<xref ref-type="bibr" rid="bibr19-0897190012448310">19</xref>
</sup> Algorithms may not be applicable to certain populations because they may overestimate therapeutic warfarin doses in elderly requiring &lt;2 mg/d.<sup>
<xref ref-type="bibr" rid="bibr43-0897190012448310">43</xref>
</sup> Most importantly, even for doses 3 to 7 mg/d where the algorithms are most accurate, the likelihood of the predicted therapeutic doses within 20% of the actual doses are 55% to 57%.<sup>
<xref ref-type="bibr" rid="bibr37-0897190012448310">37</xref>
</sup> These data suggest that warfarin doses are highly likely to be adjusted based on INR responses during warfarin initiation. Therefore, close INR monitoring is still important even if a warfarin pharmacogenomic dosing algorithm is used.</p>
<p>Clinical Pharmacogenomics Implementation Consortium (CPIC) is a multidisciplinary consortium consisting of the Pharmacogenomics Research Network members, PharmGKB staff as well as experts in pharmacogenomics, pharmacogenomics, and laboratory medicine which has published guidelines on the interpretation of the results of pharmacogenomic tests including CYP2C19 (clopidogrel) and thiopurine methyltransferase (azathiopurine, thioguanine, etc) tests.<sup>
<xref ref-type="bibr" rid="bibr44-0897190012448310">44</xref>
</sup> Their guidelines on the interpretation of warfarin pharmacogenomic test results will be published in late 2011.</p>
</sec>
</sec>
</sec>
<sec id="section10-0897190012448310">
<title>Clopidogrel</title>
<p>Clopidogrel is a thienopyridine antiplatelet widely used in patients with a history of acute coronary syndrome and/or coronary artery stent placement.<sup>
<xref ref-type="bibr" rid="bibr45-0897190012448310">45</xref>,<xref ref-type="bibr" rid="bibr46-0897190012448310">46</xref>
</sup> The drug has been shown to reduce the risk of adverse cardiovascular outcomes including in-stent thrombosis in this patient population. However, antiplatelet effect of clopidogrel is variable among patients.<sup>
<xref ref-type="bibr" rid="bibr47-0897190012448310">47</xref>
</sup> In particular, about 30% of patients taking clopidogrel are not optimally responsive to the drug.<sup>
<xref ref-type="bibr" rid="bibr47-0897190012448310">47</xref>
</sup> One of the main causes of this clopidogrel nonresponsiveness is interindividual variability in the metabolic activation of clopidogrel. Clopidogrel is a prodrug extensively metabolized by 2 metabolic pathways.<sup>
<xref ref-type="bibr" rid="bibr48-0897190012448310">48</xref>
</sup> The esterase-mediated metabolic pathway produces an inactive carboxylic metabolite that accounts for 85% of the circulating metabolites. The CYP enzyme-mediated metabolic pathway generates an active thio metabolite responsible for 15% of the circulating metabolites. Multiple CYP enzymes are involved in the CYP enzyme-mediated metabolic pathway: CYP1A2, CYP2B6, CYP2C19, and CYP3A.<sup>
<xref ref-type="bibr" rid="bibr49-0897190012448310">49</xref>
</sup> Of these enzymes, the genetic polymorphisms in <italic>CYP2C19</italic> have been associated with variable responses to clopidogrel.</p>
<sec id="section11-0897190012448310">
<title>
<italic>CYP2C19</italic> Polymorphisms</title>
<p>The <italic>CYP2C19</italic> gene is highly polymorphic. Of the over 25 known alleles, the *2, *3, and *17 alleles are common in general population. The *2 and *3 alleles encode nonfunctional enzymes.<sup>
<xref ref-type="bibr" rid="bibr7-0897190012448310">7</xref>
</sup> The *2 allele creates an aberrant splicing site in exon 5 (681G&gt;A) leading to a loss of enzyme function.<sup>
<xref ref-type="bibr" rid="bibr50-0897190012448310">50</xref>
</sup> The *3 allele introduces a premature stop codon, resulting in a truncated <italic>CYP2C19</italic> protein.<sup>
<xref ref-type="bibr" rid="bibr51-0897190012448310">51</xref>
</sup> Other alleles that produce reduced or absent <italic>CYP2C19</italic> enzyme activity include *4, *5, *6, *7, and *8. In contrast, the *17 allele increases transcriptional activity of the <italic>CYP2C19</italic> gene.<sup>
<xref ref-type="bibr" rid="bibr52-0897190012448310">52</xref>
</sup>
</p>
<p>The prevalence of the common <italic>CYP2C19</italic> variant alleles differs by race (<xref ref-type="table" rid="table5-0897190012448310">Table 5</xref>). The nonfunctional alleles are more common in Asians, whereas the *17 allele is more common in Caucasians and African Americans. Because clopidogrel requires metabolic activation for its antiplatelet effect, carriers of a <italic>CYP2C9</italic> reduced functional allele may be able to inadequately activate clopidogrel and are more likely to become clopidogrel nonresponders. A recent meta-analysis showed that clopidogrel responders may have a 3.5-fold higher risk of ischemic cardiovascular outcomes.<sup>
<xref ref-type="bibr" rid="bibr53-0897190012448310">53</xref>
</sup> Therefore, it is important to timely identify and appropriately treat clopidogrel nonresponders.</p>
<table-wrap id="table5-0897190012448310" position="float">
<label>Table 5.</label>
<caption>
<p>Prevalence of the Common <italic>CYP2C19</italic> Variant Alleles by Race (%)</p>
</caption>
<graphic alternate-form-of="table5-0897190012448310" xlink:href="10.1177_0897190012448310-table5.tif"/>
<table>
<thead>
<tr>
<th>Allele</th>
<th>Caucasians</th>
<th>African Americans</th>
<th>Asians</th>
</tr>
</thead>
<tbody>
<tr>
<td>*2</td>
<td>28</td>
<td>21</td>
<td>50</td>
</tr>
<tr>
<td>*3</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>18</td>
</tr>
<tr>
<td>*17</td>
<td>33</td>
<td>29</td>
<td>6</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0897190012448310">
<p>Abbreviation: <italic>CYP2C19</italic>, cytochrome P450 2C19.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section12-0897190012448310">
<title>
<italic>CYP2C19</italic> Genotyping Tests</title>
<p>As of August 1, 2011, 2 <italic>CYP2C19</italic> genotyping tests are available as in vitro diagnostic devices (<xref ref-type="table" rid="table6-0897190012448310">Table 6</xref>).<sup>
<xref ref-type="bibr" rid="bibr54-0897190012448310">54</xref>
</sup> These 2 tests genotype for the 3 loci (*2, *3, and *17). Some non-FDA-cleared <italic>CYP2C19</italic> tests including Infiniti<sup>®</sup> CYP450 2C19+ Assay and laboratory developed tests genotype for additional rare alleles including *4, *6, *7, *8, *9, and *10. The Infiniti <italic>CYP2C19</italic> Assay has a relatively short performance time (&lt;8 hours).</p>
<table-wrap id="table6-0897190012448310" position="float">
<label>Table 6.</label>
<caption>
<p>Clopidogrel Pharmacogenomic Tests Cleared by the Food and Drug Administration</p>
</caption>
<graphic alternate-form-of="table6-0897190012448310" xlink:href="10.1177_0897190012448310-table6.tif"/>
<table>
<thead>
<tr>
<th>Assay Name</th>
<th>
<italic>CYP2C19</italic> Alleles Tested</th>
<th>Assay Performance Time (hour)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AmpliChip<sup>®</sup> CYP450 test</td>
<td>*2 and *3</td>
<td>24-48</td>
</tr>
<tr>
<td>Infiniti<sup>®</sup> <italic>CYP2C19</italic> Assay<sup><xref ref-type="table-fn" rid="table-fn7-0897190012448310">a</xref></sup>
</td>
<td>*2, *3, and *17</td>
<td>&lt;8 </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0897190012448310">
<p>Abbreviation: CYP, cytochrome P450.</p>
</fn>
<fn id="table-fn7-0897190012448310">
<p>
<sup>a</sup> Expanded Infiniti CYP450 2C19+ Assay tests *2, *3, *4, *6, *7, *8, *9, *10, and *17.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The <italic>CYP2C19</italic> genotyping tests share with the warfarin pharmacogenomic tests the barriers to the wide spread use in clinical practice. (1) The <italic>CYP2C19</italic> genotyping tests do not genotype for other loci associated with variable clopidogrel responsiveness (eg, <italic>ABCB1</italic> 3435C&gt;T).<sup>
<xref ref-type="bibr" rid="bibr48-0897190012448310">48</xref>
</sup> As a result, <italic>CYP2C19</italic> genotyping test results may not explain all of the genetic variability causing variable clopidogrel responsiveness. (2) The tests are not available in many hospitals as an in-house test. This logistical barrier can delay turnaround time of the test results and clopidogrel is often started immediately upon presentation of patients with acute coronary syndrome. (3) Insurance companies do not usually cover the cost of the <italic>CYP2C19</italic> genotyping test ($400-$500).<sup>
<xref ref-type="bibr" rid="bibr49-0897190012448310">49</xref>
</sup> No professional organizations currently recommend <italic>CYP2C19</italic> genotyping. In addition, clinical utility of <italic>CYP2C19</italic> genotyping in patients receiving clopidogrel has not been established. In certain clinical situations (eg, stent thrombosis in a patient on clopidogrel), however, testing may be justifiable with a prior authorization. (4) It is unknown whether <italic>CYP2C19</italic> genotyping is cost-effective. Because of lack of data on the clinical utility, the cost-effectiveness of the <italic>CYP2C19</italic> genotyping has not been studied.</p>
<p>In addition, the <italic>CYP2C19</italic> genotyping tests have a unique barrier—platelet function tests. The platelet function tests determine the extent to which platelet aggregation is inhibited by clopidogrel. Studies have shown that clopidogrel inhibits platelet aggregation to a lower degree in carriers of a <italic>CYP2C19</italic>-reduced functional allele than in noncarriers.<sup>
<xref ref-type="bibr" rid="bibr55-0897190012448310">55</xref>
</sup>
</p>
<p>Although the platelet function tests do not represent complex biological mechanisms of platelet aggregation, various platelet function tests including point-of-care tests are available for clinical use and have been extensively studied for clopidogrel nonresponsiveness. These platelet function tests have sensitivities of 50% to 60%, specificities of 50% to 60%, positive predictive values of 5% to 15%, and negative predictive values of 90% to 95% for all-cause death, nonfatal myocardial infarction, stent thrombosis, and ischemic stroke.<sup>
<xref ref-type="bibr" rid="bibr56-0897190012448310">56</xref>
</sup> A recent study showed that doubling the clopidogrel maintenance dose for 6 months in clopidogrel nonresponders identified by the VerifyNow test, a point-of-care platelet function test did not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis.<sup>
<xref ref-type="bibr" rid="bibr57-0897190012448310">57</xref>
</sup> As a result, clinical utility of platelet function tests may be questionable.</p>
<p>Despite these limitations, platelet function tests are an attractive alternative to the <italic>CYP2C19</italic> genotyping tests because the results of platelet function tests are more intuitive to interpret than those of the <italic>CYP2C19</italic> genotyping tests. In addition, the point-of-care tests have a shorter assay performance time (&lt;1 hour) than the <italic>CYP2C19</italic> genotyping tests. However, many platelet function tests cannot be used in patients early after coronary stent placement because their results are influenced by the administration of a glycoprotein IIb/IIIa inhibitor widely used during the stent placement.<sup>
<xref ref-type="bibr" rid="bibr58-0897190012448310">58</xref>
</sup> In contrast, the <italic>CYP2C19</italic> genotyping tests can be used in this patient population. In addition, the platelet function tests should be conducted after clopidogrel achieves the maximum effect on the inhibition of platelet aggregation, whereas the genotyping tests can be performed before clopidogrel is administered. Moreover, the platelet function tests need special care for blood samples (eg, the use of a 21 gauge or larger needle, no shaking of the collected samples, assay completion within 4 hours of sample collection, etc),whereas the genotyping tests does not require this special care and can be performed on the tissue samples obtained noninvasively (eg, saliva tissues).</p>
<p>It is not known which type of test (eg, function vs. genetic) has better predictability of clopidogrel nonresponsiveness. Recent data show that platelet function test results are not completely correlated with the <italic>CYP2C19</italic> genotyping test results, suggesting that using these 2 different types of the tests at the same time would more likely improve the predictability of clopidogrel nonresponsiveness.<sup>
<xref ref-type="bibr" rid="bibr59-0897190012448310">59</xref>
</sup> This hypothesis, however, should be tested in a rigorous clinical trial.</p>
</sec>
<sec id="section13-0897190012448310">
<title>Evidence to Support Using Clopidogrel Pharmacogenomic Testing in Clinical Practice</title>
<p>In this section, clinical validity of clopidogrel pharmacogenomic testing will be focused because clinical utility of clopidogrel has not been studied. Although a couple of studies did not observe an association between the <italic>CYP2C19</italic> genotype and adverse cardiovascular outcomes, the current body of evidence suggests that the <italic>CYP2C19</italic> genotype is associated with clinical outcomes in patients with coronary artery disease who are on clopidogrel (<xref ref-type="table" rid="table6-0897190012448310">Table 6</xref>).<sup>
<xref ref-type="bibr" rid="bibr48-0897190012448310">48</xref>,<xref ref-type="bibr" rid="bibr60-0897190012448310">60</xref>
<xref ref-type="bibr" rid="bibr61-0897190012448310"/>
<xref ref-type="bibr" rid="bibr62-0897190012448310"/>
<xref ref-type="bibr" rid="bibr63-0897190012448310"/>
<xref ref-type="bibr" rid="bibr64-0897190012448310"/>
<xref ref-type="bibr" rid="bibr65-0897190012448310"/>
<xref ref-type="bibr" rid="bibr66-0897190012448310"/>
<xref ref-type="bibr" rid="bibr67-0897190012448310"/>
<xref ref-type="bibr" rid="bibr68-0897190012448310"/>
<xref ref-type="bibr" rid="bibr69-0897190012448310"/>
<xref ref-type="bibr" rid="bibr70-0897190012448310"/>
<xref ref-type="bibr" rid="bibr71-0897190012448310"/>
<xref ref-type="bibr" rid="bibr72-0897190012448310"/>–<xref ref-type="bibr" rid="bibr73-0897190012448310">73</xref>
</sup> The studies reporting no association generally have a population with a low risk of adverse cardiovascular outcomes (eg, noncoronary stent patients).<sup>
<xref ref-type="bibr" rid="bibr64-0897190012448310">64</xref>
</sup> Overall, the <italic>CYP2C19</italic> reduced functional alleles appear to increase the risk of adverse cardiovascular outcomes such as death from cardiovascular causes, nonfatal myocardial infarction, stent thrombosis, or stroke. A recent meta-analysis involving 9685 patients in 9 studies showed that, compared with noncarriers, carriers of 1 and 2 <italic>CYP2C19</italic>-reduced functional alleles had 55% and 76% higher risks of cardiovascular death, myocardial infarction, or ischemic stroke, respectively.<sup>
<xref ref-type="bibr" rid="bibr74-0897190012448310">74</xref>
</sup> In addition, compared with noncarriers, carriers of 1 and 2 reduced functional alleles had 2.67- and 3.97-fold higher risks of stent thrombosis, respectively. Of the reduced functional alleles, the *2 allele is the most extensively studied because it accounts for approximately 95% of the reduced functional allele carrier status. As a result, these data may not be extrapolated to the other reduced functional alleles. Although data on the effect of the <italic>CYP2C19</italic>*17 allele on adverse cardiovascular outcomes are conflicting, this allele appears to increase the risk of bleeding.<sup>
<xref ref-type="bibr" rid="bibr67-0897190012448310">67</xref>
</sup> Thus, patients taking clopidogrel with the *17 allele may need close follow-up for the risk of bleeding.</p>
<table-wrap id="table7-0897190012448310" position="float">
<label>Table 7.</label>
<caption>
<p>Summary of the Studies Relating <italic>CYP2C19</italic> Genotype to Clinical Outcomes</p>
</caption>
<graphic alternate-form-of="table7-0897190012448310" xlink:href="10.1177_0897190012448310-table7.tif"/>
<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>
<italic>CYP2C19</italic> Alleles Tested</th>
<th>Primary Outcomes</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">Substudy of a clinical trial</td>
</tr>
<tr>
<td> EXCELSIOR substudy<sup>
<xref ref-type="bibr" rid="bibr60-0897190012448310">60</xref>
</sup>
</td>
<td>797</td>
<td>*2</td>
<td>Death and MI in 1 year</td>
<td>RPA &gt;14% was associated with a higher risk of primary end points compared with RPA ≤14%. Carriers of the *2 allele had a higher percentage of RPA &gt; 14% that noncarriers (62.4% vs 43.4% after 600 mg loading, <italic>P</italic> = .001; 41.3% vs 22.5% at predischarge, <italic>P</italic> = .004).</td>
</tr>
<tr>
<td> RECLOSE substudy<sup>
<xref ref-type="bibr" rid="bibr61-0897190012448310">61</xref>
</sup>
</td>
<td>772</td>
<td>*2</td>
<td>Stent thrombosis within 6 months following PCI</td>
<td>The *2 allele is associated with a 3.43-fold increased risk of stent thrombosis (<italic>P</italic> = .047) and a 2.70-fold increased risk of stent thrombosis plus cardiac mortality (<italic>P</italic> = .049).</td>
</tr>
<tr>
<td> TRITON-TIMI38 substudy<sup>
<xref ref-type="bibr" rid="bibr62-0897190012448310">62</xref>
</sup>
</td>
<td>1477</td>
<td>*2, *3, *4, *5, *6, *7, *8, *9, *10, *12, *13, *14, *17</td>
<td>Death from cardiovascular causes, MI, or stroke</td>
<td>Carriers with a reduced functional allele had a 53% increased risk of primary end points than noncarriers (<italic>P</italic> = .01). Carriers with a reduced functional allele also had a 3-fold increased risk of stent thrombosis than noncarriers (<italic>P</italic> = .02).</td>
</tr>
<tr>
<td> ISAR substudy<sup>
<xref ref-type="bibr" rid="bibr63-0897190012448310">63</xref>
</sup>
</td>
<td>2485</td>
<td>*2</td>
<td>Stent thrombosis within 30 days following PCI</td>
<td>Carriers of the *2 allele has a 3.86-fold increased risk of primary end points compared with noncarriers (<italic>P</italic> = .006)</td>
</tr>
<tr>
<td> Substudy of CURE and ACTIVE A studies<sup>
<xref ref-type="bibr" rid="bibr64-0897190012448310">64</xref>
</sup>
</td>
<td>5059</td>
<td>*2, *3, *17</td>
<td>Cardiovascular events</td>
<td>The <italic>CYP2C19</italic>-reduced functional alleles were not associated with an increased risk of cardiovascular events. Carriers of the *17 allele received more benefits from clopidogrel as compared with placebo than noncarriers (<italic>P</italic> = .02 for interaction). Bleeding incidence did not differ by <italic>CYP2C19</italic> genotype.</td>
</tr>
<tr>
<td> A substudy of TRITON TIMI 38<sup>
<xref ref-type="bibr" rid="bibr65-0897190012448310">65</xref>
</sup>
</td>
<td>2943</td>
<td>*2, *3, *4, *5, *6, *7, *8, *9, *10, *12, *13, *14, *17</td>
<td>Death from cardiovascular causes, MI, or stroke</td>
<td>Patients with a <italic>CYP2C19</italic>-reduced functional allele had a 43% lower risk of primary end points with prasugrel than with clopidogrel (95% CI 0.39-0.83). The risk was not different in the <italic>CYP2C19</italic>*1/*1 genotype between prasugrel and clopidogrel.</td>
</tr>
<tr>
<td> PLATO substudy<sup>
<xref ref-type="bibr" rid="bibr66-0897190012448310">66</xref>
</sup>
</td>
<td>4904</td>
<td>*2, *3, *4, *5, *6, *7, *8, *17</td>
<td>Cardiovascular death, MI, or stroke</td>
<td>Carriers of a <italic>CYP2C19</italic>-reduced functional allele had a 37% higher risk of the primary end points than noncarriers (<italic>P</italic> = .028). The *17 carriers had a significantly higher incidence of major bleeding than noncarriers (<italic>P</italic> = .022).</td>
</tr>
<tr>
<td> A substudy of a prospective trial<sup>
<xref ref-type="bibr" rid="bibr67-0897190012448310">67</xref>
</sup>
</td>
<td>1524</td>
<td>*17</td>
<td>Bleeding</td>
<td>The *17 allele was associated with an 85% increased risk of bleeding (<italic>P</italic> = .006). However, the *17 allele was not associated with the risk of stent thrombosis.</td>
</tr>
<tr>
<td colspan="5">Multicenter registry study</td>
</tr>
<tr>
<td> Simon et al<sup>
<xref ref-type="bibr" rid="bibr48-0897190012448310">48</xref>
</sup>
</td>
<td>2208</td>
<td>*2, *3, *4, *5, *17</td>
<td>Death from any causes, nonfatal stroke, or MI during 1 year of follow-up</td>
<td>Carriers of 2 CYP2C19 reduced functional alleles had a 98% higher risk of primary end points than noncarriers (<italic>P</italic> = .003).</td>
</tr>
<tr>
<td> Collet et al<sup>
<xref ref-type="bibr" rid="bibr68-0897190012448310">68</xref>
</sup>
</td>
<td>259</td>
<td>*2, *3, *4, *5, *6</td>
<td>Death, MI, and urgent coronary revascularization</td>
<td>Carriers of the *2 allele had a 3.69-fold higher risk of primary end points than noncarriers (<italic>P</italic> = .0005). The carriers of the *2 allele also had a 6.02-fold higher risk of stent thrombosis than noncarriers (<italic>P</italic> = .0009).</td>
</tr>
<tr>
<td colspan="5">Single center cohort study</td>
</tr>
<tr>
<td> Shuldiner et al<sup>
<xref ref-type="bibr" rid="bibr69-0897190012448310">69</xref>
</sup>
</td>
<td>227</td>
<td>*2, *3, *5, *17</td>
<td>Ischemic cardiac event or death during 1 year of follow-up</td>
<td>Carrier of the *2 allele had a 2.42-fold higher risk of the primary end points than noncarriers (<italic>P</italic> = .02).</td>
</tr>
<tr>
<td> Malek et al<sup>
<xref ref-type="bibr" rid="bibr70-0897190012448310">70</xref>
</sup>
</td>
<td>276</td>
<td>*2</td>
<td>All-cause mortality</td>
<td>Carriers of the *2 allele tended to have a higher 4-year mortality than noncarriers (<italic>P</italic> = .09).</td>
</tr>
<tr>
<td> Tiroch et al<sup>
<xref ref-type="bibr" rid="bibr71-0897190012448310">71</xref>
</sup>
</td>
<td>928</td>
<td>*2, *17</td>
<td>Target lesion revascularization</td>
<td>Carriers of the *17 allele had a 37% lower risk of target lesion revascularization (<italic>P</italic> = .02) than noncarriers. The *2 allele was not associated with the primary end point.</td>
</tr>
<tr>
<td> Yamamoto et al<sup>
<xref ref-type="bibr" rid="bibr72-0897190012448310">72</xref>
</sup>
</td>
<td>98</td>
<td>*2, *3</td>
<td>Cardiovascular death, nonfatal MI, or ischemic stroke</td>
<td>Carriers of at least 1 reduced functional allele had a higher incidence of the primary end point than noncarriers (<italic>P</italic> value was not reported).</td>
</tr>
<tr>
<td colspan="5">Case–control study</td>
</tr>
<tr>
<td> Harmsze et al<sup>
<xref ref-type="bibr" rid="bibr73-0897190012448310">73</xref>
</sup>
</td>
<td>596</td>
<td>*2, *3</td>
<td>Stent thrombosis</td>
<td>The *2 and *3 alleles were associated with 70% and 140% increased risks of stent thrombosis, respectively (<italic>P</italic> = .018 for the *2 allele; <italic>P</italic> = .043 for the *3 allele).</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0897190012448310">
<p>Abbreviations: EXCELSIOR, Impact of Extent of Clopidogrel-Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate; RECLOSE, The Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis; TRITON-TIM 38, Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel—Thrombolysis in Myocardial Infarction 38; PLATO, PLATelet inhibition and patient Outcomes; ISAR, The Intracoronary Stenting and Antithrombotic Regimen; CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Events; ACTIVE-A, Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events; MI, Myocardial infarction; PCI, percutaneous coronary intervention; RPA, residual platelet activity; CYP2C19, cytochrome P450 2C19.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The <italic>CYP2C9</italic> polymorphisms have been shown to explain about 12% of total variability in clopidogrel response.<sup>
<xref ref-type="bibr" rid="bibr69-0897190012448310">69</xref>
</sup> Other variables associated with the total variability include body mass index, diabetes, and history of acute coronary syndrome.<sup>
<xref ref-type="bibr" rid="bibr75-0897190012448310">75</xref>
<xref ref-type="bibr" rid="bibr76-0897190012448310"/>–<xref ref-type="bibr" rid="bibr77-0897190012448310">77</xref>
</sup> In addition, noncompliance with clopidogrel is a major cause of the total variability.<sup>
<xref ref-type="bibr" rid="bibr47-0897190012448310">47</xref>
</sup> Because of the relatively small contribution to the total variability by the <italic>CYP2C19</italic> polymorphisms and the low positive predictive values of the <italic>CYP2C19</italic> genotyping tests, clinical utility of the <italic>CYP2C19</italic> genotyping should be evaluated before the testing is widely used in clinical practice. Currently, the Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI) study is evaluating the clinical utility of <italic>CYP2C19</italic> genotyping. In this single-center study, clopidogrel-naive patients with the <italic>CYP2C19</italic>*2 allele are treated with prasugrel as an alternative to clopidogrel. The study is expected to be completed in January 2013.<sup>
<xref ref-type="bibr" rid="bibr38-0897190012448310">38</xref>
</sup>
</p>
</sec>
<sec id="section14-0897190012448310">
<title>Clinical Application of Clopidogrel Pharmacogenomic Testing</title>
<p>
<italic>Who may be tested? </italic>No consensus has been made regarding who should receive <italic>CYP2C19</italic> genotyping for clopidogrel therapy. Because of the potentially devastating clinical outcomes due to clopidogrel nonresponsiveness, high-risk patients may be considered for <italic>CYP2C19 </italic>genotyping. These patients may include those with a coronary stent who develop recurrent acute coronary syndrome while they are on clopidogrel and those at a high risk of stent thrombosis based on angiographic findings. Before genotyping, it would be wise to obtain a prior authorization from the patient’s insurance.</p>
<p>
<italic>
<bold>When should the test results be available?</bold>
</italic> Ideally, clopidogrel pharmacogenomic test results should be available before the first dose of the drug. In many cases requiring urgent revascularization, however, this may not be feasible. Although the results may still be used, this delayed availability of the test results may lead to suboptimal antiplatelet therapy.</p>
<sec id="section15-0897190012448310">
<title>How can the test results be applied to patient care?</title>
<p>Noncarriers of a <italic>CYP2C19</italic>-reduced functional allele can continue 75 mg/d of clopidogrel. Because of the increased risk of bleeding, patients with the <italic>CYP2C19</italic>*17/*17 or <italic>CYP2C19</italic>*1/*17 genotype may need more vigilant monitoring on bleeding.<sup>
<xref ref-type="bibr" rid="bibr67-0897190012448310">67</xref>
</sup> For carriers of a <italic>CYP2C19</italic>-reduced functional allele, 2 main options are available. The first option is to increase the clopidogrel maintenance dose. Currently, it is unknown how much clopidogrel maintenance dose should be increased in this population. In the Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety (GRAVITAS) study which used the VerifyNow test to determine clopidogrel responder status, 150 mg/d of maintenance dose for 6 months in nonresponders did not decrease the risk of cardiovascular death, myocardial infarction, or stent thrombosis compared with 75 mg/d.<sup>
<xref ref-type="bibr" rid="bibr57-0897190012448310">57</xref>
</sup> In a recent study, 150 mg/d of maintenance dose administered to patients homozygous for a <italic>CYP2C19</italic>-reduced functional allele did not increase the percentage of responders.<sup>
<xref ref-type="bibr" rid="bibr78-0897190012448310">78</xref>
</sup> Thus, these data suggest that an increase in maintenance dose to 150 mg/d may not be sufficient. The second option is to switch to an alternative antiplatelet drug. There are three alternative antiplatelets: ticlopidine, prasugrel, and ticagrelor. The antiplatelet effect of these antiplatelets is not influenced by <italic>CYP2C19</italic> genotype.<sup>
<xref ref-type="bibr" rid="bibr55-0897190012448310">55</xref>,<xref ref-type="bibr" rid="bibr79-0897190012448310">79</xref>,<xref ref-type="bibr" rid="bibr80-0897190012448310">80</xref>
</sup> Of these drugs, prasugrel and ticagrelor may be preferred over ticlopidine because of the increased risk of neutropenia by ticlopidine. In addition, prasugrel and ticagrelor have been studied for clinical outcomes by <italic>CYP2C19</italic> genotype. In the genetic substudy of the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel—Thrombolysis in Myocardial Infarction 38 (TRITON TIMI 38), the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in the prasugrel group did not differ by the <italic>CYP2C19</italic> genotype.<sup>
<xref ref-type="bibr" rid="bibr65-0897190012448310">65</xref>
</sup> Likewise, the <italic>CYP2C19</italic> genotype did not influence the incidence of death from vascular causes, myocardial infarction, or stroke in the ticagrelor group in the PLATelet inhibition and patient Outcomes (PLATO) study.<sup>
<xref ref-type="bibr" rid="bibr66-0897190012448310">66</xref>
</sup> In addition, the incidence of bleeding in the alternative antiplatelet groups did not differ by the <italic>CYP2C19</italic> genotype.<sup>
<xref ref-type="bibr" rid="bibr65-0897190012448310">65</xref>,<xref ref-type="bibr" rid="bibr66-0897190012448310">66</xref>
</sup> These data suggest that both prasugrel and ticagrelor can be used in carriers of a <italic>CYP2C19</italic>-reduced functional allele. The CPIC guidelines also recommend prasugrel or other alternative antiplatelets for this population.<sup>
<xref ref-type="bibr" rid="bibr81-0897190012448310">81</xref>
</sup> However, these 2 drugs are not for everyone. Prasugrel is not recommended for patients with active pathological bleeding, weight &lt;60 kg, or concomitant anticoagulant use.<sup>
<xref ref-type="bibr" rid="bibr82-0897190012448310">82</xref>
</sup> Ticagrelor is contraindicated in patients with a history of intracranial hemorrhage, active pathological bleeding, and severe hepatic impairment.<sup>
<xref ref-type="bibr" rid="bibr83-0897190012448310">83</xref>
</sup> Neither drug is approved for the treatment of ischemic stroke. Thus, an alternative antiplatelet should be carefully selected based on the patient’s clinical characteristics.</p>
</sec>
</sec>
</sec>
<sec id="section16-0897190012448310">
<title>Conclusions</title>
<p>Recent advances in pharmacogenomics have made genotype-guided therapy for warfarin and clopidogrel possible: pharmacogenomic tests are available for clinical use, and treatment strategies based on the test results have been developed. However, there are many unanswered questions before the widespread use of warfarin and clopidogrel pharmacogenomic testing in clinical practice. In particular, the risk and benefit ratio of warfarin and clopidogrel pharmacogenomic testing is currently unclear. The ongoing randomized trials assessing the clinical utility of these tests will help define the roles of the pharmacogenomic tests in clinical practice. In the meantime, patients who may benefit from warfarin and clopidogrel pharmacogenomic testing should be carefully selected and the test results should be appropriately interpreted.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0897190012448310">
<label>Declaration of Conflicting Interests</label>
<p>The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0897190012448310">
<label>Funding</label>
<p>The author received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0897190012448310">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higashi</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Veenstra</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>LM</given-names>
</name>
<etal/>
</person-group> <article-title>Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy</article-title>. <source>JAMA</source>. <year>2002</year>;<volume>287</volume>(<issue>13</issue>):<fpage>1690</fpage>–<lpage>1698</lpage>.</citation>
</ref>
<ref id="bibr2-0897190012448310">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Altman</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Eriksson</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>Estimation of the warfarin dose with clinical and pharmacogenomic data</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>8</issue>):<fpage>753</fpage>–<lpage>764</lpage>.</citation>
</ref>
<ref id="bibr3-0897190012448310">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rieder</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Reiner</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Gage</surname>
<given-names>BF</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>(<issue>22</issue>):<fpage>2285</fpage>–<lpage>2293</lpage>.</citation>
</ref>
<ref id="bibr4-0897190012448310">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gage</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Eby</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group> <article-title>Use of pharmacogenomic and clinical factors to predict the therapeutic dose of warfarin</article-title>. <source>Clin Pharmacol Ther</source>. <year>2008</year>;<volume>84</volume>(<issue>3</issue>):<fpage>326</fpage>–<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr5-0897190012448310">
<label>5</label>
<citation citation-type="book">
<collab collab-type="author">Coumadin<sup>®</sup> [package insert]</collab>. <article-title>Bristol Myers Squibb Company</article-title>. <publisher-loc>Princeton, NJ</publisher-loc>; <year>2010</year>.</citation>
</ref>
<ref id="bibr6-0897190012448310">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ansell</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hirsh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hylek</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)</article-title>. <source>Chest</source>. <year>2008</year>;<volume>133</volume>(<issue>6 suppl</issue>):<fpage>160S</fpage>–<lpage>198S</lpage>.</citation>
</ref>
<ref id="bibr7-0897190012448310">
<label>7</label>
<citation citation-type="web">
<collab collab-type="author">The Human Cytochrome P450 (CYP) Allele Nomenclature Committee</collab>. <year>2008</year>. <ext-link ext-link-type="uri" xlink:href="http://www.cypalleles.ki.se/cyp2c9.htm">http://www.cypalleles.ki.se/cyp2c9.htm</ext-link>. <comment>Accessed August 1, 2011</comment>.</citation>
</ref>
<ref id="bibr8-0897190012448310">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Locuson</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Tracy</surname>
<given-names>TS</given-names>
</name>
</person-group>. <article-title>Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity</article-title>. <source>Mol Pharmacol</source>. <year>2007</year>;<volume>72</volume>(<issue>5</issue>):<fpage>1280</fpage>–<lpage>1288</lpage>.</citation>
</ref>
<ref id="bibr9-0897190012448310">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindh</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Holm</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>ML</given-names>
</name>
<etal/>
</person-group> <article-title>Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2009</year>;<volume>65</volume>(<issue>4</issue>):<fpage>365</fpage>–<lpage>375</lpage>.</citation>
</ref>
<ref id="bibr10-0897190012448310">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meckley</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Wittkowsky</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Rieder</surname>
<given-names>MJ</given-names>
</name>
<etal/>
</person-group> <article-title>An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients</article-title>. <source>Thromb Haemost</source>. <year>2008</year>;<volume>100</volume>(<issue>2</issue>):<fpage>229</fpage>–<lpage>239</lpage>.</citation>
</ref>
<ref id="bibr11-0897190012448310">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palareti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Legnani</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Guazzaloca</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Risks factors for highly unstable response to oral anticoagulation: a case-control study</article-title>. <source>Br J Haematol</source>. <year>2005</year>;<volume>129</volume>(<issue>1</issue>):<fpage>72</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr12-0897190012448310">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voora</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Eby</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Linder</surname>
<given-names>MW</given-names>
</name>
<etal/>
</person-group> <article-title>Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype</article-title>. <source>Thromb Haemost</source>. <year>2005</year>;<volume>93</volume>:<fpage>700</fpage>–<lpage>705</lpage>.</citation>
</ref>
<ref id="bibr13-0897190012448310">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanderson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Emery</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Higgins</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis</article-title>. <source>Genet Med</source>. <year>2005</year>;<volume>7</volume>(<issue>2</issue>):<fpage>97</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr14-0897190012448310">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linder</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Looney</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>JE</given-names>
<suffix> 3rd</suffix>
</name>
<etal/>
</person-group> <article-title>Warfarin dose adjustments based on CYP2C9 genetic polymorphisms</article-title>. <source>J Thromb Thrombolysis</source>. <year>2002</year>;<volume>14</volume>(<issue>3</issue>):<fpage>227</fpage>–<lpage>232</lpage>.</citation>
</ref>
<ref id="bibr15-0897190012448310">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Momary</surname>
<given-names>KM</given-names>
</name>
<etal/>
</person-group> <article-title>Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement</article-title>. <source>Blood</source>. <year>2008</year>;<volume>112</volume>:<fpage>1013</fpage>–<lpage>1021</lpage>.</citation>
</ref>
<ref id="bibr16-0897190012448310">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wadelius</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Downes</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>Common VKORC1 and GGCX polymorphisms associated with warfarin dose</article-title>. <source>Pharmacogenomics J</source>. <year>2005</year>;<volume>5</volume>(<issue>4</issue>):<fpage>262</fpage>–<lpage>270</lpage>.</citation>
</ref>
<ref id="bibr17-0897190012448310">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Limdi</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>McGwin</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group> <article-title>Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin</article-title>. <source>Clin Pharmacol Ther</source>. <year>2008</year>;<volume>83</volume>(<issue>2</issue>):<fpage>312</fpage>–<lpage>321</lpage>.</citation>
</ref>
<ref id="bibr18-0897190012448310">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwarz</surname>
<given-names>UI</given-names>
</name>
<name>
<surname>Ritchie</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Bradford</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group> <article-title>Genetic determinants of response to warfarin during initial anticoagulation</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>358</volume>(<issue>10</issue>):<fpage>999</fpage>–<lpage>1008</lpage>.</citation>
</ref>
<ref id="bibr19-0897190012448310">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Horne</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>SM</given-names>
</name>
<etal/>
</person-group> <article-title>Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>116</volume>(<issue>22</issue>):<fpage>2563</fpage>–<lpage>2570</lpage>.</citation>
</ref>
<ref id="bibr20-0897190012448310">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sconce</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>TI</given-names>
</name>
<name>
<surname>Wynne</surname>
<given-names>HA</given-names>
</name>
<etal/>
</person-group> <article-title>The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen</article-title>. <source>Blood</source>. <year>2005</year>;<volume>106</volume>(<issue>7</issue>):<fpage>2329</fpage>–<lpage>2333</lpage>.</citation>
</ref>
<ref id="bibr21-0897190012448310">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perini</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Struchiner</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Silva-Assuncao</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Pharmacogenomics of warfarin: development of a dosing algorithm for brazilian patients</article-title>. <source>Clin Pharmacol Ther</source>. <year>2008</year>;<volume>84</volume>(<issue>6</issue>):<fpage>722</fpage>–<lpage>728</lpage>.</citation>
</ref>
<ref id="bibr22-0897190012448310">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cavallari</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Langaee</surname>
<given-names>TY</given-names>
</name>
<name>
<surname>Momary</surname>
<given-names>KM</given-names>
</name>
<etal/>
</person-group> <article-title>Genetic and clinical predictors of warfarin dose requirements in African Americans</article-title>. <source>Clin Pharmacol Ther</source>. <year>2010</year>;<volume>87</volume>(<issue>4</issue>):<fpage>459</fpage>–<lpage>464</lpage>.</citation>
</ref>
<ref id="bibr23-0897190012448310">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caldwell</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Awad</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group> <article-title>CYP4F2 genetic variant alters required warfarin dose</article-title>. <source>Blood</source>. <year>2008</year>;<volume>111</volume>(<issue>8</issue>):<fpage>4106</fpage>–<lpage>4112</lpage>.</citation>
</ref>
<ref id="bibr24-0897190012448310">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loebstein</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dvoskin</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Halkin</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group> <article-title>A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance</article-title>. <source>Blood</source>. <year>2007</year>;<volume>109</volume>(<issue>6</issue>):<fpage>2477</fpage>–<lpage>2480</lpage>.</citation>
</ref>
<ref id="bibr25-0897190012448310">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kadafour</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Haugh</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Posin</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Survey on warfarin pharmacogenomic testing among anticoagulation providers</article-title>. <source>Pharmacogenomics</source>. <year>2009</year>;<volume>10</volume>(<issue>11</issue>):<fpage>1853</fpage>–<lpage>1860</lpage>.</citation>
</ref>
<ref id="bibr26-0897190012448310">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ginsburg</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Voora</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>The long and winding road to warfarin pharmacogenomic testing</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>55</volume>(<issue>25</issue>):<fpage>2813</fpage>–<lpage>2815</lpage>.</citation>
</ref>
<ref id="bibr27-0897190012448310">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meckley</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>PJ</given-names>
</name>
</person-group>. <article-title>Personalized medicine: factors influencing reimbursement</article-title>. <source>Health Policy</source>. <year>2009</year>;<volume>94</volume>(<issue>2</issue>):<fpage>91</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr28-0897190012448310">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eckman</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Rosand</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>SM</given-names>
</name>
<etal/>
</person-group> <article-title>Cost-effectiveness of using pharmacogenomic information in warfarin dosing for patients with nonvalvular atrial fibrillation</article-title>. <source>Ann Intern Med</source>. <year>2009</year>;<volume>150</volume>(<issue>2</issue>):<fpage>73</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr29-0897190012448310">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>You</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Tsui</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>RS</given-names>
</name>
<etal/>
</person-group> <article-title>Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy</article-title>. <source>Clin Pharmacol Ther</source>. <year>2009</year>;<volume>86</volume>(<issue>5</issue>):<fpage>540</fpage>–<lpage>547</lpage>.</citation>
</ref>
<ref id="bibr30-0897190012448310">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meckley</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Gudgeon</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>JL</given-names>
</name>
<etal/>
</person-group> <article-title>A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing</article-title>. <source>Pharmacoeconomics</source>. <year>2010</year>;<volume>28</volume>:<fpage>61</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr31-0897190012448310">
<label>31</label>
<citation citation-type="web">
<collab collab-type="author">Genomic testing</collab>. <article-title>Centers for Disease Control and Prevention</article-title>, <year>2010</year>. <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/genomics/gtesting/ACCE/">http://www.cdc.gov/genomics/gtesting/ACCE/</ext-link>. <comment>Accessed August 1, 2011</comment>.</citation>
</ref>
<ref id="bibr32-0897190012448310">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Epstein</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Moyer</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Aubert</surname>
<given-names>RE</given-names>
</name>
<etal/>
</person-group> <article-title>Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study)</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>55</volume>:<fpage>2804</fpage>–<lpage>2812</lpage>.</citation>
</ref>
<ref id="bibr33-0897190012448310">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caraco</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Blotnick</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Muszkat</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study</article-title>. <source>Clin Pharmacol Ther</source>. <year>2008</year>;<volume>83</volume>(<issue>3</issue>):<fpage>460</fpage>–<lpage>470</lpage>.</citation>
</ref>
<ref id="bibr34-0897190012448310">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XQ</given-names>
</name>
<etal/>
</person-group> <article-title>Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients</article-title>. <source>Pharmacogenet Genomics</source>. <year>2009</year>;<volume>19</volume>(<issue>3</issue>):<fpage>226</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr35-0897190012448310">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burmester</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Yale</surname>
<given-names>SH</given-names>
</name>
<etal/>
</person-group> <article-title>A randomized controlled trial of genotype-based Coumadin initiation</article-title>. <source>Genet Med</source>. <year>2011</year>;<volume>13</volume>(<issue>6</issue>):<fpage>509</fpage>–<lpage>518</lpage>.</citation>
</ref>
<ref id="bibr36-0897190012448310">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singer</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Albers</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Dalen</surname>
<given-names>JE</given-names>
</name>
<etal/>
</person-group>. <article-title>Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)</article-title>. <source>Chest</source>. <year>2008</year>;<volume>133</volume>(<issue>6 suppl</issue>):<fpage>546S</fpage>–<lpage>192S</lpage>.</citation>
</ref>
<ref id="bibr37-0897190012448310">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Comparison of warfarin pharmacogenomic dosing algorithms in a racially diverse large cohort</article-title>. <source>Pharmacogenomics</source>. <year>2011</year>;<volume>12</volume>:<fpage>125</fpage>–<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr38-0897190012448310">
<label>38</label>
<citation citation-type="web">
<collab collab-type="author">Clinicaltrials.gov</collab>. <article-title>National Institute of Health</article-title>. <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">http://clinicaltrials.gov/</ext-link>. <comment>Accessed August 1, 2011</comment>.</citation>
</ref>
<ref id="bibr39-0897190012448310">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thacker</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Grice</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Milligan</surname>
<given-names>PE</given-names>
</name>
<etal/>
</person-group> <article-title>Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes</article-title>. <source>J Thromb Haemost</source>. <year>2008</year>;<volume>6</volume>:<fpage>1445</fpage>–<lpage>1449</lpage>.</citation>
</ref>
<ref id="bibr40-0897190012448310">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lenzini</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wadelius</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kimmel</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Integration of genetic, clinical, and INR data to refine warfarin dosing</article-title>. <source>Clin Pharmacol Ther</source>. <year>2010</year>;<volume>87</volume>:<fpage>572</fpage>–<lpage>578</lpage>.</citation>
</ref>
<ref id="bibr41-0897190012448310">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finkelman</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Gage</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group> <article-title>Genetic warfarin dosing: tables versus algorithms</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year>;<volume>57</volume>(<issue>5</issue>):<fpage>612</fpage>–<lpage>618</lpage>.</citation>
</ref>
<ref id="bibr42-0897190012448310">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kayser</surname>
<given-names>SR</given-names>
</name>
</person-group>. <article-title>Accuracy of the pharmacogenomic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort</article-title>. <source>Pharmacotherapy</source> <year>2011</year>;<fpage>31</fpage>. <comment>In press</comment>.</citation>
</ref>
<ref id="bibr43-0897190012448310">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Kane</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>Failure of pharmacogenomic-based dosing algorithms to identify older patients requiring low daily doses of warfarin</article-title>. <source>J Am Med Dir Assoc</source>. <year>2011</year>. <comment>In press</comment>.</citation>
</ref>
<ref id="bibr44-0897190012448310">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Relling</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>TE</given-names>
</name>
</person-group>. <article-title>CPIC: clinical pharmacogenomics implementation consortium of the pharmacogenomics research network</article-title>. <source>Clin Pharmacol Ther</source>. <year>2011</year>;<volume>89</volume>:<fpage>464</fpage>–<lpage>467</lpage>.</citation>
</ref>
<ref id="bibr45-0897190012448310">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>JL</given-names>
</name>
</person-group>, <article-title>Adams CD, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>123</volume>:<fpage>2022</fpage>–<lpage>2060</lpage>.</citation>
</ref>
<ref id="bibr46-0897190012448310">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antman</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Hand</surname>
<given-names>M</given-names>
</name>
</person-group>, <article-title>Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;<volume>51</volume>:<fpage>210</fpage>–<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr47-0897190012448310">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Fernandez-Ortiz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bernardo</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>49</volume>:<fpage>1505</fpage>–<lpage>1516</lpage>.</citation>
</ref>
<ref id="bibr48-0897190012448310">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simon</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Verstuyft</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mary-Krause</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Genetic determinants of response to clopidogrel and cardiovascular events</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>:<fpage>363</fpage>–<lpage>375</lpage>.</citation>
</ref>
<ref id="bibr49-0897190012448310">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Momary</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Dorsch</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Bates</surname>
<given-names>ER</given-names>
</name>
</person-group>. <article-title>Genetic causes of clopidogrel nonresponsiveness: which ones really count?</article-title> <source>Pharmacotherapy</source>. <year>2010</year>;<volume>30</volume>:<fpage>265</fpage>–<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr50-0897190012448310">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Morais</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Blaisdell</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans</article-title>. <source>J Biol Chem</source>. <year>1994</year>;<volume>269</volume>:<fpage>15419</fpage>–<lpage>15422</lpage>.</citation>
</ref>
<ref id="bibr51-0897190012448310">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Morais</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Blaisdell</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese</article-title>. <source>Mol Pharmacol</source>. <year>1994</year>;<volume>46</volume>:<fpage>594</fpage>–<lpage>598</lpage>.</citation>
</ref>
<ref id="bibr52-0897190012448310">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sim</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Risinger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>ML</given-names>
</name>
<etal/>
</person-group> <article-title>A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants</article-title>. <source>Clin Pharmacol Ther</source>. <year>2006</year>;<volume>79</volume>:<fpage>103</fpage>–<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr53-0897190012448310">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Combescure</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fontana</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mallouk</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis</article-title>. <source>J Thromb Haemost</source>. <year>2010</year>;<volume>8</volume>(<issue>5</issue>):<fpage>923</fpage>–<lpage>933</lpage>.</citation>
</ref>
<ref id="bibr54-0897190012448310">
<label>54</label>
<citation citation-type="web">
<collab collab-type="author">510(k) Premarket Notification</collab>. <article-title>The US Food and Drug Administration</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm">http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm</ext-link>. <comment>Accessed August 1, 2011</comment>.</citation>
</ref>
<ref id="bibr55-0897190012448310">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varenhorst</surname>
<given-names>C</given-names>
</name>
<name>
<surname>James</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Erlinge</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease</article-title>. <source>Eur Heart J</source>. <year>2009</year>;<volume>30</volume>(<issue>14</issue>):<fpage>1744</fpage>–<lpage>1752</lpage>.</citation>
</ref>
<ref id="bibr56-0897190012448310">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breet</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>van Werkum</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Bouman</surname>
<given-names>HJ</given-names>
</name>
<etal/>
</person-group> <article-title>Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation</article-title>. <source>JAMA</source>. <year>2010</year>;<volume>303</volume>(<issue>8</issue>):<fpage>754</fpage>–<lpage>762</lpage>.</citation>
</ref>
<ref id="bibr57-0897190012448310">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Price</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Teirstein</surname>
<given-names>PS</given-names>
</name>
<etal/>
</person-group> <article-title>Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial</article-title>. <source>JAMA</source>. <year>2011</year>;<volume>305</volume>:<fpage>1097</fpage>–<lpage>1105</lpage>.</citation>
</ref>
<ref id="bibr58-0897190012448310">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gurbel</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>KG</given-names>
</name>
<etal/>
</person-group> <article-title>Platelet function monitoring in patients with coronary artery disease</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>50</volume>:<fpage>1822</fpage>–<lpage>1834</lpage>.</citation>
</ref>
<ref id="bibr59-0897190012448310">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gurbel</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Shuldiner</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Bliden</surname>
<given-names>KP</given-names>
</name>
<etal/>
</person-group> <article-title>The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy</article-title>. <source>Am Heart J</source>. <year>2011</year>;<volume>161</volume>:<fpage>598</fpage>–<lpage>604</lpage>.</citation>
</ref>
<ref id="bibr60-0897190012448310">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trenk</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hochholzer</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Fromm</surname>
<given-names>MF</given-names>
</name>
<etal/>
</person-group> <article-title>Cytochrome P450 2C19 681G&gt;A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;<volume>51</volume>:<fpage>1925</fpage>–<lpage>1934</lpage>.</citation>
</ref>
<ref id="bibr61-0897190012448310">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giusti</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gori</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Marcucci</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis</article-title>. <source>Am J Cardiol</source>. <year>2009</year>;<volume>103</volume>:<fpage>806</fpage>–<lpage>811</lpage>.</citation>
</ref>
<ref id="bibr62-0897190012448310">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mega</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Close</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Wiviott</surname>
<given-names>SD</given-names>
</name>
<etal/>
</person-group> <article-title>Cytochrome p-450 polymorphisms and response to clopidogrel</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>:<fpage>354</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr63-0897190012448310">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sibbing</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Stegherr</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Latz</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group> <article-title>Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention</article-title>. <source>Eur Heart J</source>. <year>2009</year>;<volume>30</volume>:<fpage>916</fpage>–<lpage>922</lpage>.</citation>
</ref>
<ref id="bibr64-0897190012448310">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pare</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of CYP2C19 genotype on outcomes of clopidogrel treatment</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>:<fpage>1704</fpage>–<lpage>1714</lpage>.</citation>
</ref>
<ref id="bibr65-0897190012448310">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sorich</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Vitry</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>MB</given-names>
</name>
<etal/>
</person-group> <article-title>Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data</article-title>. <source>J Thromb Haemost</source>. <year>2010</year>;<volume>8</volume>:<fpage>1678</fpage>–<lpage>1684</lpage>.</citation>
</ref>
<ref id="bibr66-0897190012448310">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>James</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Storey</surname>
<given-names>RF</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>376</volume>:<fpage>1320</fpage>–<lpage>1328</lpage>.</citation>
</ref>
<ref id="bibr67-0897190012448310">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sibbing</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Gebhard</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>121</volume>:<fpage>512</fpage>–<lpage>518</lpage>.</citation>
</ref>
<ref id="bibr68-0897190012448310">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collet</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Hulot</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Pena</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study</article-title>. <source>Lancet</source>. <year>2009</year>;<volume>373</volume>:<fpage>309</fpage>–<lpage>317</lpage>.</citation>
</ref>
<ref id="bibr69-0897190012448310">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shuldiner</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>O'Connell</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Bliden</surname>
<given-names>KP</given-names>
</name>
<etal/>
</person-group> <article-title>Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>302</volume>:<fpage>849</fpage>–<lpage>857</lpage>.</citation>
</ref>
<ref id="bibr70-0897190012448310">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malek</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Przyluski</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Spiewak</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction</article-title>. <source>Cardiology</source>. <year>2010</year>;<volume>117</volume>:<fpage>81</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr71-0897190012448310">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiroch</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Sibbing</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group> <article-title>Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events</article-title>. <source>Am Heart J</source>. <year>2010</year>;<volume>160</volume>:<fpage>506</fpage>–<lpage>512</lpage>.</citation>
</ref>
<ref id="bibr72-0897190012448310">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hokimoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chitose</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy</article-title>. <source>J Cardiol</source> <year>2011</year>;<volume>57</volume>:<fpage>194</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr73-0897190012448310">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harmsze</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>van Werkum</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Ten Berg</surname>
<given-names>JM</given-names>
</name>
<etal/>
</person-group> <article-title>CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study</article-title>. <source>Eur Heart J</source>. <year>2010</year>;<volume>31</volume>:<fpage>3046</fpage>–<lpage>3053</lpage>.</citation>
</ref>
<ref id="bibr74-0897190012448310">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mega</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Collet</surname>
<given-names>JP</given-names>
</name>
<etal/>
</person-group> <article-title>Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis</article-title>. <source>JAMA</source>. <year>2010</year>;<volume>304</volume>:<fpage>1821</fpage>–<lpage>1830</lpage>.</citation>
</ref>
<ref id="bibr75-0897190012448310">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Fernandez-Ortiz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bernardo</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?</article-title> <source>J Invasive Cardiol</source>. <year>2004</year>;<volume>16</volume>:<fpage>169</fpage>–<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr76-0897190012448310">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Fernandez-Ortiz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bernardo</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment</article-title>. <source>Diabetes</source>. <year>2005</year>;<volume>54</volume>(<issue>8</issue>):<fpage>2430</fpage>–<lpage>2435</lpage>.</citation>
</ref>
<ref id="bibr77-0897190012448310">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soffer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Moussa</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Harjai</surname>
<given-names>KJ</given-names>
</name>
<etal/>
</person-group> <article-title>Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?</article-title> <source>Catheter Cardiovasc Interv</source>. <year>2003</year>;<volume>59</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr78-0897190012448310">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barker</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Teirstein</surname>
<given-names>PS</given-names>
</name>
<etal/>
</person-group> <article-title>Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2010</year>;<volume>3</volume>:<fpage>1001</fpage>–<lpage>1007</lpage>.</citation>
</ref>
<ref id="bibr79-0897190012448310">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tantry</surname>
<given-names>US</given-names>
</name>
<name>
<surname>Bliden</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies</article-title>. <source>Circ Cardiovasc Genet</source>. <year>2010</year>;<volume>3</volume>:<fpage>556</fpage>–<lpage>566</lpage>.</citation>
</ref>
<ref id="bibr80-0897190012448310">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maeda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Asai</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine</article-title>. <source>Clin Pharmacol Ther</source>. <year>2011</year>;<volume>89</volume>(<issue>2</issue>):<fpage>229</fpage>–<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr81-0897190012448310">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scott</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Sangkuhl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>EE</given-names>
</name>
<etal/>
</person-group> <article-title>Clinical pharmacogenomics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy</article-title>. <source>Clin Pharmacol Ther</source>. <year>2011</year>;<volume>90</volume>(<issue>2</issue>):<fpage>328</fpage>–<lpage>332</lpage>.</citation>
</ref>
<ref id="bibr82-0897190012448310">
<label>82</label>
<citation citation-type="web">
<collab collab-type="author">Effient [Package Insert]</collab>. <article-title>Eli Lilly and Company</article-title>, <year>2010</year>. <ext-link ext-link-type="uri" xlink:href="http://pi.lilly.com/us/effient.pdf">http://pi.lilly.com/us/effient.pdf</ext-link>. <comment>Accessed August 1, 2011</comment>.</citation>
</ref>
<ref id="bibr83-0897190012448310">
<label>83</label>
<citation citation-type="web">
<collab collab-type="author">Brilinta [Package Insert]</collab>. <article-title>Astrazeneca</article-title>, <year>2011</year>. <ext-link ext-link-type="uri" xlink:href="http://www1.astrazeneca-us.com/pi/brilinta.pdf">http://www1.astrazeneca-us.com/pi/brilinta.pdf</ext-link>. <comment>Accessed Ausgust 1, 2011</comment>.</citation>
</ref>
</ref-list>
</back>
</article>